Managing T-DXd Toxicity: ILD, Nausea, Fatigue & What to Watch For

While T-DXd has transformed HER2-positive breast cancer, managing ILD risk remains a top priority. This clip breaks down why a cough can never wait until the next visit, how to navigate fatigue and nausea with dose-reduction strategies, and why early symptom recognition is the key to maintaining long-term treatment.